Rakhi Kumar Sells 227,500 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Roivant Sciences Trading Down 0.1 %

Roivant Sciences stock opened at $10.67 on Thursday. The firm has a market capitalization of $7.61 billion, a P/E ratio of -71.13 and a beta of 1.25. Roivant Sciences Ltd. has a twelve month low of $9.76 and a twelve month high of $13.06. The stock’s fifty day simple moving average is $11.25 and its 200-day simple moving average is $11.59.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its holdings in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after purchasing an additional 1,948 shares in the last quarter. Gladius Capital Management LP purchased a new position in Roivant Sciences in the third quarter valued at $35,000. US Bancorp DE raised its stake in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Roivant Sciences during the 4th quarter worth about $39,000. Finally, GAMMA Investing LLC boosted its position in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ROIV. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.